Form 8-K - Current report:
SEC Accession No. 0001104659-24-119783
Filing Date
2024-11-15
Accepted
2024-11-15 17:19:52
Documents
13
Period of Report
2024-11-15
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2428553d1_8k.htm   iXBRL 8-K 32599
  Complete submission text file 0001104659-24-119783.txt   208978

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA egrx-20241115.xsd EX-101.SCH 3012
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE egrx-20241115_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE egrx-20241115_pre.xml EX-101.PRE 22357
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2428553d1_8k_htm.xml XML 3690
Mailing Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677
Business Address 50 TICE BOULEVARD, SUITE 315 WOODCLIFF LAKE NJ 07677 201-326-5300
EAGLE PHARMACEUTICALS, INC. (Filer) CIK: 0000827871 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36306 | Film No.: 241468931
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)